VASCUCAP Trademark

Trademark Overview

On Sunday, February 2, 2014, a trademark application was filed for VASCUCAP with the United States Patent and Trademark Office. The USPTO has given the VASCUCAP trademark a serial number of 86182064. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Thursday, February 4, 2021. This trademark is owned by Elucid Bioimaging Inc.. The VASCUCAP trademark is filed in the Medical & Beauty Services & Agricultural Services category with the following description:

Medical services, namely, quantitating imaging services to evaluate the severity of vascular disease, in particular, atherosclerosis, and assess longitudinal therapeutic response to investigational therapeutic agents to vascular disease
vascucap

General Information

Serial Number86182064
Word MarkVASCUCAP
Filing DateSunday, February 2, 2014
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateThursday, February 4, 2021
Registration Number4636011
Registration DateTuesday, November 11, 2014
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 26, 2014

Trademark Statements

Goods and ServicesMedical services, namely, quantitating imaging services to evaluate the severity of vascular disease, in particular, atherosclerosis, and assess longitudinal therapeutic response to investigational therapeutic agents to vascular disease

Classification Information

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, February 13, 2014
Primary Code044
First Use Anywhere DateFriday, April 26, 2013
First Use In Commerce DateFriday, April 26, 2013

Trademark Owner History

Party NameElucid Bioimaging Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressBoston, MA 02116
Party NameElucid Bioimaging Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWenham, MA 01984
Party NameElucid Bioimaging Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWenham, MA 01984

Trademark Events

Event DateEvent Description
Monday, July 7, 2014EXAMINERS AMENDMENT -WRITTEN
Wednesday, February 5, 2014NEW APPLICATION ENTERED
Thursday, February 13, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, May 7, 2014ASSIGNED TO EXAMINER
Monday, May 12, 2014NON-FINAL ACTION WRITTEN
Monday, May 12, 2014NON-FINAL ACTION E-MAILED
Monday, May 12, 2014NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, July 7, 2014EXAMINERS AMENDMENT E-MAILED
Monday, July 7, 2014NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, July 7, 2014EXAMINER'S AMENDMENT ENTERED
Tuesday, November 11, 2014REGISTERED-PRINCIPAL REGISTER
Monday, July 7, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, July 22, 2014ASSIGNED TO LIE
Thursday, July 24, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, August 6, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 26, 2014PUBLISHED FOR OPPOSITION
Tuesday, August 26, 2014OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Thursday, February 4, 2021NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Monday, November 11, 2019COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Monday, October 26, 2020TEAS SECTION 8 & 15 RECEIVED
Tuesday, February 2, 2021CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, February 4, 2021REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Tuesday, October 22, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, October 22, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, October 22, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, October 22, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, October 22, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, November 11, 2023COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED

Related Keywords

vascucap therapeutic vascular disease services longitudinal assess response agents investigational atherosclerosis